Clinical Utility of Rush Venom Immunotherapy. Clinical Utility of Rush Venom Immunotherapy: Current Status

Archive ouverte

Gruzelle, Vianney | Mailhol, Claire | Waters, David, W | Guilleminault, Laurent

Edité par CCSD ; Dove Press -

International audience. Hymenoptera venom allergy (HVA) is the leading cause of anaphylactic reactions in adults and the second most common cause in children. Venom immunotherapy (VIT) is used to elicit an immune tolerance against hymenoptera venom in allergic patients and is based on the administration of purified venom extracts regularly for defined periods. The protocols of administration include 2 phases: an up-dosing phase that incrementally reaches the final dose resulting in a protective effect, and a maintenance phase in order to obtain the sustained effect. The goal of this review is to detail the efficacy and the safety of the up-dosing phase also named rush. Pathophysiological mechanisms, indications of VIT and technical aspects of up-dosing protocol are also covered

Suggestions

Du même auteur

NOVEOS and ImmunoCAP Have Similar Performances for Diagnosing Food Allergies

Archive ouverte | Trouche-Estival, Benjamin | CCSD

International audience. Background: The clinical significance of newly available platforms for specific IgE measurement must be evaluated. However, data are lacking for NOVEOS (Hycor), especially for food allergens....

Overweight and bronchospasm during general anaesthesia: An association with heterogeneous mechanisms. Overweight and bronchospasm during general anaesthesia: An association with heterogeneous mechanisms: An association with heterogeneous mechanisms

Archive ouverte | Dardé, Xavier | CCSD

International audience. Anaphylaxis during anaesthesia is a life-threatening conditionwith an estimated incidence of approximately 1:10,000.1 Broncho-spasm during general anaesthesia is classically associated with a...

Management of initial colonisations with Burkholderia species in France, with retrospective analysis in five cystic fibrosis Centres: a pilot study

Archive ouverte | Gruzelle, Vianney | CCSD

International audience. Abstract Background Whereas Burkholderia infections are recognized to impair prognosis in cystic fibrosis (CF) patients, there is no recommendation to date for early eradication therapy. The ...

Chargement des enrichissements...